title: Prognostic Value of MicroRNA-182 in Cancers: A Meta-Analysis.
abstract: OBJECTIVE
  MicroRNA-182 (miR-182) exhibits altered expression in various cancers. The aim of this study was to investigate the predictive value of miR-182 expression for cancer patient survival.
  
  
  METHODS
  Eligible studies were identified through multiple search strategies, and the hazard ratios (HRs) for patient outcomes were extracted and estimated. A meta-analysis was performed to evaluate the prognostic value of miR-182.
  
  
  RESULTS
  In total, 14 studies were included. A high miR-182 expression level predicted a worse outcome with a pooled HR of 2.18 (95% CI: 1.53-3.11) in ten studies related to overall survival (OS), especially in Chinese populations. The results of seven studies evaluating disease-free survival/relapse-free survival/recurrence-free interval/disease-specific survival (DFS/RFS/RFI/DSS) produced a pooled HR of 1.77 (95% CI: 0.91-3.43), which was not statistically significant; however, the trend was positive. When disregarding the DSS from one study, the expression of miR-182 was significantly correlated with DFS/RFS/RFI (pooled HR = 2.52, 95% CI: 1.67-3.79).
  
  
  CONCLUSIONS
  High miR-182 expression is associated with poor OS and DFS/RFS/RFI in some types of cancers, and miR-182 may be a useful prognostic biomarker for predicting cancer prognosis. However, given the current insufficient relevant data, further clinical studies are needed.
authors.affiliation: Department of Hematology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China.
authors.forename: Fei
authors.identifier: 0000-0002-1122-5286
authors.initials: F
authors.lastname: Wang
authors.affiliation: Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing 210009, China.
authors.forename: Shanliang
authors.identifier: 0000-0001-8200-0511
authors.initials: S
authors.lastname: Zhong
authors.affiliation: Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China.
authors.forename: Haijun
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Pathology, Medical School, Southeast University, Nanjing 210009, China.
authors.forename: Wei
authors.identifier: 0000-0003-3304-9161
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Hematology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China.
authors.forename: Hongming
authors.identifier: 0000-0003-0928-7784
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Hematology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China.
authors.forename: Xue
authors.identifier: 0000-0002-9002-844X
authors.initials: X
authors.lastname: Wu
authors.affiliation: Department of Hematology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China.
authors.forename: Baoan
authors.initials: B
authors.lastname: Chen
mesh_terms: D018572:Disease-Free Survival; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D009369:Neoplasms / Q000208:ethnology / Q000235:genetics* / Q000401:mortality*; D011379:Prognosis; D016019:Survival Analysis; D015854:Up-Regulation
chemical_list: D035683:MicroRNAs; C538984:Mirn182 microRNA, human